Wolverine Blend is a healing & repair research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Wolverine Blend is a pre-mixed lyophilized research formulation combining BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 synthetic analogue) in a single vial. Each compound targets tissue repair through mechanistically distinct but complementary pathways: BPC-157 promotes angiogenesis, gastrointestinal cytoprotection, and musculotendinous repair via nitric oxide and growth factor signalling; TB-500 drives actin dynamics, cell migration, and anti-inflammatory signalling via thymosin beta-4's sequestration of G-actin and activation of ILK (Integrin-Linked Kinase). The rationale for combination use is that these mechanisms operate in parallel, with BPC-157 primarily influencing vascular and GI repair and TB-500 primarily influencing skeletal muscle, connective tissue, and cardiac tissue remodelling. Available in 5 mg+5 mg and 10 mg+10 mg per vial formats.
Preclinical studies examining BPC-157 and TB-500 individually in overlapping injury models provide the scientific basis for the combination. In rodent models of tendon, ligament, and musculoskeletal injury, BPC-157 accelerates tendon-to-bone healing and tenocyte proliferation while TB-500 enhances satellite cell mobilisation and myofibre regeneration — endpoints that are measured by different histological and functional assays. Research examining the combination aims to characterise whether their repair-promoting activities are additive or synergistic, using collagen synthesis, hydroxyproline content, breaking strength biomechanics, and immunohistochemistry for repair markers (CD31 for angiogenesis, PCNA for proliferation, alpha-SMA for myofibroblast activity).
PeptidesFromChina.co supplies Wolverine Blend as lyophilized powder in sealed vials. Each component is verified individually for purity by HPLC and confirmed by mass spectrometry before blending. Certificates of Analysis are available per batch. Wholesale quantities on request. For laboratory research use only.
| Formulation Type | Pre-mixed Lyophilized Research Blend |
|---|---|
| Component 1 | BPC-157 — 5 mg or 10 mg per vial |
| Component 2 | TB-500 — 5 mg or 10 mg per vial |
| Available Formats | 5+5 mg / vial and 10+10 mg / vial |
| BPC-157 Mechanism | Angiogenesis, cytoprotection, NO/VEGF signalling |
| TB-500 Mechanism | Actin sequestration (G-actin/Tβ4), ILK activation, cell migration |
| Research Category | Tissue Repair, Musculoskeletal, Healing & Recovery |
| Storage | -20°C lyophilized; 4°C reconstituted (up to 14 days) |
| CAS Number | N/A — combination product |
| Molecular Weight | N/A — see individual component COAs |
| Molecular Formula | N/A — combination product |
| Sequence | N/A — combination product |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| BPC-157 5mg + TB-500 5mg | 10 mg | 10 vials | ≥98% | In Stock | $119.00 |
| BPC-157 10mg + TB-500 10mg | 20 mg | 10 vials | ≥98% | In Stock | $225.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis (COA) is included with every order. Documentation covers purity, molecular weight, and batch identification.
Both BPC-157 and TB-500 have been independently studied in Achilles tendon transection, anterior cruciate ligament (ACL) injury, and rotator cuff models in rats. BPC-157's angiogenic activity (VEGFR-2 upregulation, NO-mediated vasodilation) promotes vascularisation of the avascular tendon midsubstance during healing. TB-500's enhancement of satellite cell migration and actin remodelling supports myofibre regeneration in the adjacent musculature. Combination studies use histology (H&E, Masson's trichrome for collagen), biomechanical testing (failure load, stiffness), and immunofluorescence for repair markers to characterise whether both mechanisms operate simultaneously and independently at the injury site.
BPC-157 has an established preclinical cytoprotective profile in gastric ulcer, NSAID-induced GI lesion, and inflammatory bowel disease models, largely attributed to its stable gastric pentadecapeptide properties and upregulation of cytoprotective signalling (EGR-1, COX-2, NOS pathways). TB-500's systemic anti-inflammatory activity — via downregulation of NF-κB and reduction of inflammatory cytokine expression — may complement BPC-157's local GI protection in research designs examining systemic inflammation with concurrent GI stress. Combination assay designs use acetic acid ulcer models and TNBS colitis rodent protocols with concurrent systemic injury markers.
TB-500 has documented cardioprotective effects in myocardial infarction rodent models — cardiac-specific thymosin beta-4 overexpression studies established its role in cardiomyocyte survival and coronary vessel formation. BPC-157 has been studied in fistula, anastomosis healing, and venous occlusion models relevant to vascular surgery research. The combination is of interest for cardiac I/R injury models where both angiogenic (BPC-157) and myocyte-protective (TB-500) mechanisms may contribute to infarct size reduction, measured by TTC staining, echocardiographic ejection fraction, and histological scar area.
A methodological research question for combination peptide formulations is the optimal ratio and timing of administration relative to injury. Pre-treatment, concurrent, and post-injury dosing protocols have different implications for repair mechanisms, particularly whether vascularisation (BPC-157-dependent) must precede or accompany cellular migration (TB-500-dependent) for optimal healing. Dose-ranging studies using the 1:1 ratio (as in the Wolverine Blend formulation) versus variable ratios in specific injury models characterise whether one component dominates the repair response or both contribute proportionally.
BPC-157 and TB-500 operate through mechanistically distinct repair pathways. BPC-157 primarily drives angiogenesis and cytoprotective signalling via NO, VEGF, and EGR-1 pathways. TB-500 primarily drives cell migration, actin dynamics, and satellite cell mobilisation via thymosin beta-4 G-actin sequestration and ILK activation. In tissue repair, vascularisation (BPC-157) and cellular migration/regeneration (TB-500) are required sequentially and simultaneously — providing a scientific rationale for combination use. The 1:1 ratio in the Wolverine Blend formulation allows researchers to study the combined profile without independently sourcing and mixing the compounds.
Yes. Each component is verified separately by RP-HPLC (≥98% purity) and ESI-MS identity confirmation before combination. The lyophilized blend vial contains both peptides at the stated ratio. Individual Certificates of Analysis for each component are available along with the combined batch documentation.
Yes, with assay design considerations. In cell culture formats, the two compounds in the blend act independently at their respective receptor targets — BPC-157 at relevant growth factor receptors and TB-500's active sequence (Ac-SDKP) at membrane signalling complexes. Researchers should ensure the assay cell type expresses receptors relevant to both compounds, or use single-compound controls alongside the blend to distinguish individual contributions to the measured endpoint.
Yes. Wolverine Blend (BPC-157 + TB-500) is available through PeptidesFromChina.co in 5+5 mg and 10+10 mg vial formats on a B2B wholesale basis. Volume pricing and minimum order quantities are provided on request after account verification.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.